- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07676864
Eye Tracking for Early Identification of Post-ICU Cognitive Impairment
Early Identification of Post-ICU Cognitive Impairment Using Eye-Tracking Technology: A Prospective Observational Study
Some patients may have problems with memory, attention, thinking speed, or other cognitive functions after leaving the intensive care unit (ICU). This is called post-ICU cognitive impairment. Early recognition of this problem may help clinicians provide follow-up care and support more promptly.
This study will explore whether eye-tracking technology can help identify cognitive impairment in patients soon after ICU discharge. Eye tracking is a non-invasive test that records eye movements while a person looks at images or completes simple visual tasks on a screen. The test does not involve any treatment or change in usual medical care.
Participants will be adult patients who have been transferred from the ICU to a general ward. Within 7 days after ICU discharge, participants will complete a cognitive assessment and an eye-tracking test. The study team will also collect relevant clinical information from medical records. Patients will be grouped according to whether they have post-ICU cognitive impairment based on cognitive assessment and clinical judgment.
The main purpose of this study is to assess whether information obtained from eye-tracking tests can help clinicians identify possible post-ICU cognitive impairment at an early stage, when used together with standard cognitive assessment. The study will also compare eye movement patterns between the two groups and explore whether eye-tracking measures add useful information beyond standard cognitive assessment.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Post-intensive care syndrome-cognitive impairment (PICS-CI) is a common problem among patients after discharge from the intensive care unit (ICU). It may involve difficulties with memory, attention, executive function, information processing speed, visuospatial ability, or language. These problems may affect long-term recovery, quality of life, treatment adherence, and social participation. Early identification of possible cognitive impairment after ICU discharge is therefore important for follow-up care and rehabilitation planning.
Current assessment of post-ICU cognitive impairment mainly relies on cognitive screening scales and clinical judgment. Although these methods are widely used, they may be influenced by a patient's level of cooperation, education, emotional state, fatigue, and subjective responses. Eye-tracking technology provides objective and quantitative information about eye movement behavior during visual and cognitive tasks. Because eye movements are closely related to attention, inhibitory control, visual processing, and other cognitive processes, eye-tracking-derived parameters may provide additional information to support early cognitive screening after ICU discharge.
This is a prospective, single-center, observational study conducted at Zhongshan Hospital, Fudan University. The study will enroll patients who have been transferred from the ICU to a general ward after ICU treatment. No treatment, medication, device intervention, or change in usual clinical care will be assigned by the study. All study procedures will be performed on the basis of routine care and are intended for research assessment only.
Within 7 days after ICU discharge, participants will complete a standardized cognitive assessment and an eye-tracking test. Cognitive status will be assessed using the Montreal Cognitive Assessment (MoCA), with education-based score correction, together with clinical judgment under the DSM-5 framework for neurocognitive disorders. Based on this assessment, participants will be classified as having post-ICU cognitive impairment or not having post-ICU cognitive impairment.
During the eye-tracking test, participants will complete predefined visual cognitive tasks in a standardized testing environment. Eye movement data will be recorded using eye-tracking equipment and processed using Tobii Pro Lab software according to predefined areas of interest, time windows, and saccade identification rules. Eye-tracking-derived parameters may include saccade latency, saccade accuracy, saccade error rate, mean saccade amplitude, mean saccade velocity, mean saccade duration, fixation time, and uncorrected error rate. These parameters will be used to describe eye movement behavior related to response initiation, attention orientation, inhibitory control, spatial localization, eye movement execution, and visual processing.
The study team will also collect demographic and clinical information from medical records, including age, sex, education level, ICU-related clinical characteristics, disease severity, ICU length of stay, mechanical ventilation, sedative and analgesic exposure, and other clinically relevant factors. These data will be used to describe the study population and to adjust for potential confounding factors in the analysis.
The main objective of this study is to evaluate whether eye-tracking-derived parameters, alone or in combination, can support the early identification of post-ICU cognitive impairment as an auxiliary tool to standard cognitive assessment. The study will compare eye movement characteristics between patients with and without post-ICU cognitive impairment and examine the association between eye-tracking-derived parameters and cognitive status. The diagnostic performance of selected eye-tracking parameters or parameter combinations will be evaluated using receiver operating characteristic curve analysis. Exploratory models may also assess whether adding eye-tracking-derived parameters to clinical and cognitive assessment information improves identification performance.
Eye tracking is non-invasive and does not involve radiation, medication, or invasive procedures. Some participants may experience temporary eye fatigue, visual discomfort, dizziness, nausea, or other mild discomfort while looking at the screen or completing the visual tasks. The research team will monitor participants during testing and may pause or stop the test if needed. All collected data will be de-identified and managed according to the study data management plan to protect participant privacy and data security.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ai rong Zhu, Bachelor's Degree
- Numéro de téléphone: +86 15160007359
- E-mail: 2471015405@qq.com
Lieux d'étude
-
-
-
Shanghai, Chine
- Zhongshan hospital, Fudan university
-
Contact:
- Yuxia Zhang, PhD
- Numéro de téléphone: +86 13816881925
- E-mail: zhang.yuxia@zs-hospital.sh.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Successfully transferred from the ICU to a general ward after ICU treatment.
- ICU length of stay of at least 24 hours.
- Conscious and able to cooperate with cognitive assessment and eye-tracking tests.
- Willing to participate in the study and able to provide written informed consent.
Exclusion Criteria:
- Diagnosed with cognitive impairment before ICU admission, such as Alzheimer's disease, based on medical history or previous medical records.
- Previous diagnosis of mental illness or intellectual developmental disorder.
- Severe visual, hearing, or eye disease that prevents completion of cognitive assessment or eye-tracking tasks.
- Severe neurological disease that may affect cognitive function, such as stroke, traumatic brain injury, or intracranial infection.
- Unable to understand or complete the cognitive assessment or eye-tracking tasks due to severe fatigue, marked inattention, communication disorder, or other reasons as assessed by the research staff.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Post-ICU Cognitive Impairment Group
Participants diagnosed with post-ICU cognitive impairment based on DSM-5 criteria, clinical assessment, and corrected MoCA score.
|
|
Non-Post-ICU Cognitive Impairment Group
Participants without post-ICU cognitive impairment based on DSM-5 criteria, clinical assessment, and corrected MoCA score.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Auxiliary Identification Performance of Eye-Tracking-Derived Parameters for Post-ICU Cognitive Impairment
Délai: Within 7 days after ICU discharge
|
The area under the receiver operating characteristic curve (AUC) will be used to evaluate how well selected eye-tracking-derived parameters, alone or in combination, support the identification of post-ICU cognitive impairment.
Post-ICU cognitive impairment will be determined using DSM-5 neurocognitive disorder criteria together with clinical assessment and education-corrected Montreal Cognitive Assessment (MoCA) score.
|
Within 7 days after ICU discharge
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Occurrence of Post-ICU Cognitive Impairment
Délai: Within 7 days after ICU discharge
|
The proportion of enrolled participants classified as having post-ICU cognitive impairment will be summarized.
Post-ICU cognitive impairment will be determined using DSM-5 neurocognitive disorder criteria together with clinical assessment and education-corrected MoCA score.
|
Within 7 days after ICU discharge
|
|
Differences in Eye-Tracking-Derived Parameters Between Cognitive Status Groups
Délai: Within 7 days after ICU discharge
|
Eye-tracking-derived parameters will be compared between participants with and without post-ICU cognitive impairment.
Parameters may include saccade latency, saccade accuracy, saccade error rate, mean saccade amplitude, mean saccade velocity, mean saccade duration, fixation time, and uncorrected error rate.
|
Within 7 days after ICU discharge
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- B2026-360
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .